Arvinas
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
ARVN Key Statistics
Stock Snapshot
The current Arvinas(ARVN) stock price is $7.51, with a market capitalization of 491.7M. The stock trades at a price-to-earnings (P/E) ratio of 47.32.
As of 2026-09-28, Arvinas(ARVN) stock has fluctuated between $7.39 and $7.60. The current price stands at $7.51, placing the stock +1.7% above today's low and -1.2% off the high.
Arvinas(ARVN) shares are trading with a volume of 469.65K, against a daily average of 1.01M.
During the past year, Arvinas(ARVN) stock moved between $6.97 at its lowest and $14.51 at its peak.
During the past year, Arvinas(ARVN) stock moved between $6.97 at its lowest and $14.51 at its peak.
ARVN News
Arvinas (ARVN) announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting C...
...
Analyst ratings
50%
of 16 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.